FDA grants orphan drug designation to glioblastoma treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
Glioma
Glioma overview
Gliomas are a group of brain tumors that arise from glial cells, a type of support cell of the central nervous system, or CNS, which comprises the brain and spinal cord. They make up about one-quarter of all tumors that start in the brain (primary brain tumors), occurring in about 6.6 per 100,000 people every year. They also account for more than 80% of all malignant, or cancerous, brain tumors.
Read moreGlioma treatment
Treatment for gliomas, a diverse group of tumors that form in the brain and spinal cord, can involve a variety of approaches, including surgery, radiation therapy, and chemotherapy, as well as a range of supportive treatments.
Read moreNews
Iopofosine I 131 may improve survival in pediatric brain cancer
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
Voranigo becomes 1st therapy in EU to target IDH-mutated glioma
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
Clinical trial testing BPM31510 for glioblastoma now fully enrolled
Enrollment is now complete in a Phase 2b clinical trial testing Bpgbio’s BPM31510, a treatment candidate for glioblastoma multiforme (GBM), a rapidly progressing type…
Modeyso added to NCCN guidelines for rare brain cancer
The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include Modeyso (dordaviprone) as an appropriate option for a rare recurrent…
New strategy targets the ‘mesh’ around tumors to stop glioblastoma
Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…
